工程化细胞外囊泡对病毒性心肌炎的多靶向免疫调节治疗

核心信息

• 论文英文标题: Multitargeted Immunomodulatory Therapy for Viral Myocarditis by Engineered Extracellular Vesicles
• 期刊: ACS Nano
• 发表年份: 2024
• DOI: 10.1021/acsnano.3c05847
• PMID/PMCID: 38232382

研究概览

Therefore, we developed cardiac-targeting peptide (CTP) and platelet membrane (PM)-engineered M2 EVs enriched with viral macrophage inflammatory protein-II (vMIP-II), termed CTP/PM-M2 EVsvMIP-II-Lamp2b, to improve the delivery of EVs "cargo" to the heart tissues. Taken together, our findings suggest that CTP-and-PM-engineered M2 EVsvMIP-II-Lamp2b represent an effective means for treating VM and show promise for clinical applications.

核心发现

Immune regulation therapies are considered promising for treating classically activated macrophage (M1)-driven viral myocarditis (VM).

Alternatively, activated macrophage (M2)-derived extracellular vesicles (M2 EVs) have great immunomodulatory potential owing to their ability to reprogram macrophages, but their therapeutic efficacy is hampered by insufficient targeting capacity in vivo.

Therefore, we developed cardiac-targeting peptide (CTP) and platelet membrane (PM)-engineered M2 EVs enriched with viral macrophage inflammatory protein-II (vMIP-II), termed CTP/PM-M2 EVsvMIP-II-Lamp2b, to improve the delivery of EVs "cargo" to the heart tissues.

In a mouse model of VM, the intravenously injected CTP/PM-M2 EVsvMIP-II-Lamp2b could be carried into the myocardium via CTP, PM, and vMIP-II.

Echo Biotech 角色

Exosupur试剂盒分离M2巨噬细胞来源外泌体

关联平台: Exoomics®, Research Reagents & Tools

关联服务与能力: EV Isolation & Purification, Research Reagent / Product Supply

关联产品或试剂: Exosupur® EV Isolation/Purification Kit

参考文献

原始论文: Multitargeted Immunomodulatory Therapy for Viral Myocarditis by Engineered Extracellular Vesicles ACS Nano. 2024. DOI: 10.1021/acsnano.3c05847. PMID/PMCID: 38232382.